[Rhabdomyolysis caused by simvastatinin a patient following heart transplantation and cyclosporine therapy].
Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are cholesterol-lowering agents which may induce rhabdomyolysis. The authors present a case of rhabdomyolysis attributed to simvastatin in a heart-transplant recipient. They stress the probability of a dose-dependent muscular toxicity and the risk of overdosage in patients already under treatment with drugs that interfere with the pharmacokinetics of HMG-CoA reductase inhibitors, notably ciclosporine.
Blaison
G
G
Unité d'Immunopathologie, CHU, Strasbourg.
Weber
J C
JC
Sachs
D
D
Korganow
A S
AS
Martin
T
T
Kretz
J G
JG
Pasquali
J L
JL
D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D016572:Cyclosporine / Q000493:pharmacokinetics*; D004336:Drug Antagonism; D016027:Heart Transplantation; D006801:Humans; D008148:Lovastatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012206:Rhabdomyolysis / Q000139:chemically induced*; D019821:Simvastatin
D000924:Anticholesteremic Agents; D016572:Cyclosporine; D008148:Lovastatin; D019821:Simvastatin
Rhabdomyolyse causée par la simvastatine chez un transplanté cardiaque sous ciclosporine.